Captrust Financial Advisors Atreca, Inc. Transaction History

Captrust Financial Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$1.56 - $3.25 $2,235 - $4,657	-1,433 Reduced 72.67%	539 $1,000
Q1 2022 May 16, 2022	BUY	$1.61 - $5.2 $2,340 - $7,560	1,454 Added 280.69%	1,972 $6,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $533 - $1,169	186 Added 56.02%	518 $2,000
Q3 2021 Nov 16, 2021	BUY	$4.91 - $9.07 $893 - $1,650	182 Added 121.33%	332 $2,000
Q1 2021 May 17, 2021	BUY	$13.0 - $19.34 $1,755 - $2,610	135 Added 900.0%	150 $2,000
Q2 2020 Aug 14, 2020	BUY	$12.52 - $23.45 $187 - $351	15 New	15 $0

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.